Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1: GU tumours, non-prostate

LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results

Date

11 Sep 2022

Session

Mini Oral session 1: GU tumours, non-prostate

Topics

Clinical Research;  Immunotherapy;  Radiation Oncology;  Surgical Oncology

Tumour Site

Urothelial Cancer

Presenters

Sebastian Schmid

Citation

Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089

Authors

S.C. Schmid1, K. Schiller2, J. Lewerich1, A.K. Seitz3, A. Sauter4, F. Koll1, F. Beckert1, P. Korn1, P. Maisch5, C. Rödel6, M. Flentje7, T. Wiegel8, S. Combs2, F. Zengerling5, C. Bolenz5, H. Kuebler3, J. Gschwend1, M. Retz1

Author affiliations

  • 1 Urology, TUM - Technical University of Munich, 81675 - München/DE
  • 2 Radiation Oncology, TUM - Technical University of Munich, 80333 - Munich/DE
  • 3 Urology, UKW - University Hospital Würzburg, 97080 - Würzburg/DE
  • 4 Radiology, TUM - Technical University of Munich, 81675 - München/DE
  • 5 Urology, Ulm Medical University, 89081 - Ulm/DE
  • 6 Radiotherapy, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), 60590 - Frankfurt am Main/DE
  • 7 Radiation Oncology, UKW - University Hospital Würzburg, 97080 - Würzburg/DE
  • 8 Radiation Oncology, Ulm Medical University, 89081 - Ulm/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA75

Background

Patients (Pts) with locally advanced bladder cancer (BC) have a poor prognosis despite radical surgical therapy. Early data on neoadjuvant immunotherapy in muscle invasive BC is promising, while there are indications of synergistic effects of radiation and immunotherapy. This trial evaluates the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy (RIT) following radical cystectomy (RCX) in patients with locally advanced, muscle invasive BC.

Methods

Patients with locally advanced urothelial BC (cT3/4 cN0/N+ cM0, eligible for RCX, unfit for or refusing neoadjuvant chemotherapy) were included in this prospective, single arm, phase II-trial. Pts were treated with Nivolumab 240mg intravenously every two weeks for 4 cycles, starting one week before radiotherapy of the bladder/pelvis with 50.4 Gy, followed by RCX with standardized pelvic lymphadenectomy. Primary endpoint is the rate of Pts with completed treatment (RIT and RCX) at the end of week 15. Secondary endpoints include overall response rate (ORR), pathological response rates, disease free survival (DFS) and toxicity.

Results

Of 33 treated Pts, 32 (97%) were ≥cT3/4 and 10 (30.3%) were lymph node positive (cN+). For primary endpoint and efficacy analysis, 31 Pts were eligible. Primary endpoint of completed treatment (RIT and RCX) in time at the end of week 15 was reached in 27/31 (87.1%) Pts. Median number of nivolumab cycles was 4. The radiological ORR was 70.9% (CR 16.1%, PR 54.8%, SD 25.8% and PD 3.2%). Pathological response rate was ypT0 38.7% and ≤ ypT1 58.1%. While survival data is immature, DFS rate at 12 months was 90.6%. Any-grade treatment-related AEs (TRAEs) occurred in 54.5 % of all 33 patients. TRAEs were mostly grade 1-2. Most common TRAEs were thyroid and gastrointestinal disorders (each 15.2%) and skin reactions (33.3%). TRAEs led to Nivolumab discontinuation in 8 (25.8%) Pts.

Conclusions

The trial met its primary endpoint. Neoadjuvant radio-immunotherapy followed by radical cystectomy in locally advanced bladder cancer patients is feasible and safe.

Clinical trial identification

NCT03529890, first posted: May 18, 2018.

Editorial acknowledgement

Legal entity responsible for the study

Faculty of Medicine, Technical University of Munich.

Funding

Bristol Myers Squibb.

Disclosure

S.C. Schmid: Financial Interests, Personal, Invited Speaker: Ipsen, Astellas; Financial Interests, Institutional, Funding: Bristol-Myers Squibb; Non-Financial Interests, Personal, Travel expenses: Janssen; Financial Interests, Personal, Travel expenses: Novartis. A.K. Seitz: Financial Interests, Personal, Congress invitation: Bristol Myers Squibb. F. Zengerling: Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker, Travel: Bayer Health; Financial Interests, Personal, Invited Speaker, Advisory Boards: Bristol-Myers Squibb, Novartis, Roche, Sanofi-Aventis; Financial Interests, Personal, Invited Speaker, Advisory Boards, Travel: Ipsen, Pfizer, Merck Healthcare; Financial Interests, Personal, Advisory Board, Travel: Janssen-Cilag; Financial Interests, Personal, Advisory Board: MSD. C. Bolenz: Financial Interests, Personal, Invited Speaker: Janssen-Cilag GmbH, AstraZeneca GmbH, Medac GmbH, Takeda Pharma GmbH, Roche Pharma AG, Ipsen Pharma GmbH; Financial Interests, Personal, Advisory Board: Roche Pharma AG, ERBE Elektromedizin GmbH. J. Gschwend: Financial Interests, Institutional, Sponsor/Funding: Bristol Myers Squibb. M. Retz: Financial Interests, Institutional, Sponsor/Funding: Bristol Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.